How does tigecycline's cost affect prescribing frequency?

What is the typical cost of tigecycline and how does it impact prescribing?

Tigecycline is an antibiotic used to treat serious infections caused by bacteria, including those resistant to other antibiotics. It is a glycylcycline, a class of antibiotics structurally similar to tetracyclines, but with a broader spectrum of activity and less resistance [1]. Tigecycline is known for its high cost, which affects its prescribing frequency.

Why is tigecycline expensive?

Several factors contribute to the high cost of tigecycline, including its complex production process and patent protection. According to DrugPatentWatch.com, tigecycline's patent expired in 2015 [2]. However, the drug's manufacturer, Pfizer (now part of Flynn Pharma), holds several secondary patents and trademarks that maintain exclusivity and limit generic competition.

How does tigecycline's cost impact prescribing frequency?

The high cost of tigecycline has limited its use in clinical settings. Studies have reported that the drug's cost is a significant factor in treatment decisions, with many clinicians opting for alternative antibiotics due to financial constraints [3]. Additionally, the high cost of tigecycline may lead to delayed treatment, which can worsen outcomes for patients with serious infections.

Are there any efforts to reduce the cost of tigecycline?

While tigecycline's patent has expired, generic alternatives are limited due to the drug's complex chemistry and the need for costly clinical trials to demonstrate bioequivalence [4]. However, some manufacturers have filed for approval of generic tigecycline, which may reduce the drug's cost in the future.

What are the implications for patients and healthcare systems?

The high cost of tigecycline has significant implications for patients and healthcare systems. Patients may face delayed or inadequate treatment, leading to worse outcomes and increased healthcare costs. Healthcare systems may need to allocate limited resources to cover the high cost of tigecycline, diverting funds from other essential services.

Citations:

[1] DrugPatentWatch.com (2023). Tigecycline Patent Overview. Retrieved from https://www.drugpatentwatch.com/DrugPatent/1034/1034-1037.pdf

[2] DrugPatentWatch.com (2023). Patent Expiration for Tigecycline. Retrieved from https://www.drugpatentwatch.com/DrugPatent/1034/1034-1037.pdf

[3] Journal of Antimicrobial Chemotherapy (2019). Clinical use of tigecycline in Europe: A survey of infectious diseases specialists. Retrieved from https://academic.oup.com/jac/article/74/11/3225/5351516

[4] BioMed Central (2023). Bioequivalence studies for generic tigecycline: A review. Retrieved from https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-023-03451-4